Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen’s Prolia Gains EU Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Amgen’s Prolia Gains EU Approval

Amgen has received approval from the EMEA for Prolia (denosumab) for osteoporosis.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen has received approval from the EMEA for Prolia (denosumab) for osteoporosis. The drug’s initial indication will be for women with post-menopausal osteoporosis and men with prostate cancer who, as a result of hormone therapy, are at increased risk of bone fractures.

Prolia is administered every six months by injection and is the first in a new class of drugs designed to inhibit proteins that activate bone-destroying cells. The drug is currently under review by the FDA and a decision is expected by late July.

The drug is also being developed for expanded use in cancer patients.
Amgen and GlaxoSmithKline will collaborate to commercialize the drug in Europe for osteoporosis, while Amgen will retain full rights for North America and for oncology indications in Europe. GSK will be responsible for sales in emerging markets.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters